Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 30, 2026
UBS (UBS) Reports Strong Q2 2026 Results with +17% Profit Growth

UBS (UBS) Reports Strong Q2 2026 Results with +17% Profit Growth

Key Takeaways

  • Net profit reached $2.8 billion in the second quarter, comfortably exceeding the analyst consensus estimate of $2.39 billion and rising 17% year over year.
  • Global Wealth Management attracted $36 billion in net new assets, significantly outpacing analyst forecasts of roughly $21 billion, underscoring strong client confidence in the combined UBS–Credit Suisse franchise.
  • The Investment Bank posted a record second-quarter performance, with pre-tax profit more than doubling to $1.2 billion, driven by surging equities trading and capital markets activity.
  • A new $3 billion share buyback program was announced, with at least $1 billion expected to be repurchased over the next three months, following the completion of the prior $3 billion program in July.
  • Cumulative cost savings from the Credit Suisse integration reached $12.6 billion, representing more than 90% of the $13.5 billion target, with the integration on track for substantial completion by year-end 2026.
  • The internal workforce fell below 100,000 for the first time since the Credit Suisse acquisition, reflecting disciplined headcount management as legacy IT systems are decommissioned.

Earnings Context and Why It Matters

UBS Group AG's second-quarter 2026 results mark a pivotal moment in the bank's post-acquisition journey. Nearly three years after the government-brokered rescue of Credit Suisse, this earnings release provides the clearest evidence yet that the merger thesis is delivering on its promises. With integration milestones accelerating, cost savings materializing ahead of schedule, and client flows remaining robust, the quarter offered investors a tangible progress report on one of the most complex banking integrations in modern history. The results also arrive at a critical juncture for Swiss banking regulation, as Parliament deliberates on capital requirements that could materially shape UBS's future capital return capacity. For the market, this earnings report serves as a dual test: sustaining organic business momentum while navigating unresolved regulatory headwinds.

The Reported Numbers

UBS reported net profit attributable to shareholders of $2.8 billion for the second quarter of 2026, exceeding the company-provided analyst consensus of $2.39 billion. Earnings per share (EPS) came in at $0.87, while group revenue rose 16% year over year to $13.3 billion. Underlying pre-tax profit surged 45% to $3.9 billion, and the underlying return on CET1 capital reached 16.4%.

Global Wealth Management generated $2 billion in pre-tax profit, up 38% from the prior-year quarter, supported by $36 billion in net new assets. The Investment Bank delivered exceptional results with pre-tax profit of $1.2 billion — more than double the year-ago figure — on revenue of $3.7 billion, a 31% increase. Asset Management posted pre-tax profit of $237 million, up 9%, with assets under management surpassing $2.2 trillion. The Personal and Corporate Banking division contributed CHF 676 million in pre-tax profit, a 21% increase, while group credit loss expenses remained contained at CHF 61 million.

The bank's CET1 capital ratio stood at 14.4% at quarter-end, and the group's cost-to-income ratio improved to 70% on an underlying basis. Cumulative gross cost savings from the Credit Suisse integration reached $12.6 billion, placing UBS well within reach of its $13.5 billion target. Total invested assets across the group climbed to a record $7.3 trillion. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Market Reaction and Investor Sentiment

UBS shares rose approximately 1% to 3% in early trading following the results, with the stock trading near the upper end of its 52-week range. The positive but measured market reaction reflected a balance between strong underlying performance and lingering cautiousness around the pace of future capital returns. While net profit comfortably beat consensus, headline EPS of $0.87 fell slightly short of some third-party estimates, and revenue was broadly in line with or marginally below certain forecasts. Analysts at Vontobel noted that the earnings beat was concentrated in investment banking trading, with the other three operating divisions exceeding consensus by a narrower margin. Nonetheless, the $36 billion wealth management inflow — nearly double some analyst forecasts — and the new $3 billion buyback commitment were widely viewed as signals of confidence from management. Sentiment heading into the quarter had been cautiously optimistic, and the results largely validated that positioning, though unresolved Swiss capital regulation remains a key overhang for longer-term institutional investors.

Forward Outlook and Key Factors to Monitor

Looking ahead, UBS enters the second half of 2026 with several tailwinds and a few unresolved challenges. The most immediate catalyst for investors is the progress of Swiss parliamentary deliberations on capital requirements for systemically important banks, with the next key committee session scheduled for mid-August. The proposed framework could require UBS to hold an additional $20 billion or more in CET1 capital against its foreign subsidiaries — a requirement CEO Sergio Ermotti has publicly described as excessive and competitively damaging. Any softening of that stance by lawmakers would likely be received positively by the market and could unlock a faster pace of share buybacks beyond the newly announced $3 billion program.

On the operational side, the Credit Suisse integration is approaching its final chapter. With over 90% of legacy IT applications no longer in use and roughly 70% already fully decommissioned, UBS is targeting substantial completion by the end of 2026. Achieving this milestone would remove one of the largest execution risks that has hung over the stock since the 2023 acquisition.

Investors should also monitor wealth management flows in the Americas, where elevated advisor attrition has created pockets of client outflow. The division posted $1 billion in net inflows during Q2 even after a $10 billion seasonal tax-related outflow, offering early signs of stabilization. Meanwhile, management cautioned that geopolitical uncertainty, volatile energy prices, and potential shifts in inflation and interest rate expectations could create temporary headwinds in the third quarter, even as underlying client activity remains healthy and supportive of continued revenue growth. I reviewed recent patterns with Tickeron’s AI Real Time Patterns to gauge potential near-term moves.

Using Tickeron’s AI Screener in My Research

When evaluating financial names like this one, I often turn to Tickeron’s AI Screener to filter peers by metrics such as revenue growth, capital ratios, and AI signals. It helps me quickly spot how UBS stacks up against the broader sector without spending hours on manual screens.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: UBS

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


UBS's RSI Oscillator ascends from oversold territory

The RSI Oscillator for UBS moved out of oversold territory on September 25, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 25 similar instances when the indicator left oversold territory. In 22 of the 25 cases the stock moved higher. This puts the odds of a move higher at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +4.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where UBS advanced for three days, in 235 of 349 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.

UBS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 193 of 332 cases where UBS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 58%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 14, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on UBS as a result. In 46 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 60%.

The Moving Average Convergence Divergence Histogram (MACD) for UBS turned negative on September 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 22 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 54%.

UBS moved below its 50-day moving average on September 14, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for UBS crossed bearishly below the 50-day moving average on September 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 53%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where UBS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 5 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 11 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 20, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating fairly steady price growth. UBS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 59 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.706) is normal, around the industry mean (1.887). P/E Ratio (16.895) is within average values for comparable stocks, (15.079). Projected Growth (PEG Ratio) (0.694) is also within normal values, averaging (2.038). Dividend Yield (0.022) settles around the average of (0.026) among similar stocks. P/S Ratio (3.209) is also within normal values, averaging (3.867).

The Tickeron PE Growth Rating for this company is 66 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are JPMorgan Chase & Co (NYSE:JPM), Bank of America Corp (NYSE:BAC), HSBC Holdings PLC (NYSE:HSBC), Wells Fargo & Co (NYSE:WFC), Citigroup (NYSE:C), Barclays PLC (NYSE:BCS).

Industry description

Major banks are among the biggest companies in the world, often times with global reach and market capitalizations in the multi-billions. Large banks often have multiple arms spanning different disciplines, from deposits, to investment banking, to wealth management and insurance. The biggest banks often have key competitive advantages over smaller players in the industry in terms of brand recognition, cost of capital, and efficiency. Think J.P. Morgan, Bank of America, Wells Fargo, and Citigroup.

Market Cap

The average market capitalization across the Major Banks Industry is 208.75B. The market cap for tickers in the group ranges from 1.04M to 911.92B. JPM holds the highest valuation in this group at 911.92B. The lowest valued company is BACRP at 1.04M.

High and low price notable news

The average weekly price growth across all stocks in the Major Banks Industry was -1%. For the same Industry, the average monthly price growth was -2%, and the average quarterly price growth was 31%. C experienced the highest price growth at 2%, while WFC experienced the biggest fall at -4%.

Volume

The average weekly volume growth across all stocks in the Major Banks Industry was -39%. For the same stocks of the Industry, the average monthly volume growth was 17% and the average quarterly volume growth was -30%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 68
P/E Growth Rating: 32
Price Growth Rating: 44
SMR Rating: 4
Profit Risk Rating: 20
Seasonality Score: -29 (-100 ... +100)
View a ticker or compare two or three
UBS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a major bank

Industry MajorBanks

Industry
Major Banks
Address
Bahnhofstrasse 45
Phone
+41 442341111
Employees
105236
Web
https://www.ubs.com
Interact to see
Advertisement
Shares of VALN are plummeting approximately 35% in Monday's session, from a Friday close of $10.66 to roughly $6.93, in heavy volume trading. The primary catalyst is the release of Phase 3 VALOR trial topline results for Valneva's Lyme disease vaccine candidate, co-developed with PFE (Pfizer) — results that showed strong clinical efficacy but failed to meet the pre-determined statistical criterion for the primary endpoint.
AXTI is surging approximately +11.00% in Monday's session, trading near $60.21, up from a prior closing price of $54.24. The move extends the stock's post-earnings rally that began last Thursday when shares jumped more than 19% following AXT's Q4 2025 results.
Tower Semiconductor (TSEM) shares are surging approximately +10% intraday on Monday, March 23, trading around $180, up from the previous close of $163.63 on March 20, 2026. The primary catalyst is the opening day of APEC 2026 in San Antonio, Texas, where Tower Semiconductor is presenting its newly unveiled Gen3 BCD power management platform designed to address escalating AI data center power demands.
CD is indicated down about 17% in premarket trading after the latest completed session, pointing to a sharp negative market reaction heading into the open. The stock’s weakness comes against a backdrop of lingering uncertainty following its privatization and delisting process from Nasdaq, which has left limited liquidity and a thinner news flow around the name.
SEDG is indicated down roughly 9% in premarket trading, following a strong advance in the prior regular session. The pullback comes after shares rallied on optimism around new product launches and an analyst upgrade, leaving the stock vulnerable to profit-taking and volatility.
NTGR shares surged approximately 11% in premarket trading on March 24, 2026, building on a roughly 20% overnight jump in the prior session. The primary catalyst is a landmark Federal Communications Commission (FCC) ruling that prohibits all imports of consumer routers manufactured overseas, citing national security concerns.
ANNA is surging approximately +20.00% in Tuesday's premarket session, rebounding sharply from Monday's -22.84% decline. The primary catalyst remains the ongoing U.S.-Iran military conflict, which disrupted Qatari LNG exports and drove European benchmark natural gas prices to multi-year highs.
Concentrix Corporation (CNXC) shares are falling approximately 11% in Tuesday's premarket session after the company released its fiscal Q1 2026 earnings report before market open. Adjusted diluted EPS came in at $2.61, missing the Wall Street consensus estimate of approximately $2.64.
Shares of Karyopharm Therapeutics (KPTI) are trading approximately 12% lower in Tuesday's premarket session, with the previous close at $7.63. The primary catalyst is the March 24 release of topline Phase 3 SENTRY trial data, in which the company met only one of two co-primary endpoints.
IBRX shares are down approximately 23% in Tuesday's session, trading near $7.24 after closing at $9.40 on Monday, March 23. The sharp decline follows an 11%+ surge in the prior session, with profit-taking and valuation pressure cited as primary triggers.
Shares of Circle Internet Group (CRCL) are down approximately 9% in Tuesday morning trading, extending a pullback from recent multi-month highs above $126. The primary catalyst appears to be a broad crypto-sector risk-off wave, with Bitcoin sliding below $69,000 and the Fear & Greed Index dropping to extreme fear territory.
ALM shares are indicated down about 11% in early Tuesday trading after closing the prior session at $16.93. The move comes after a powerful multi‑month rally that took the stock from below $3 to an intraday high of $22.55 earlier in March, leaving it vulnerable to profit-taking and volatility.​
LUNR shares are indicated down about 7% in Tuesday premarket trading after closing the last regular session at $20.31. The pullback follows a powerful rally driven by strong 2026 revenue guidance of $900 million–$1 billion and upbeat analyst commentary, including price target hikes and buy ratings.
MAZE shares are trading approximately 27% lower in premarket on March 25, 2026, after the company reported its highly anticipated Phase 2 HORIZON trial topline data for lead drug candidate MZE829. The catalyst is a dual announcement: Phase 2 clinical data for MZE829 in APOL1-mediated kidney disease (AMKD) alongside Q4 and full-year 2025 financial results.
ARM shares surged approximately +10% in premarket trading on March 25, 2026, hitting $148.6 from a prior close of approximately $135. The primary catalyst is Arm's historic strategic pivot: the company announced it will begin selling its own self-developed AGI CPU chips, breaking its decades-long "IP licensing only" business model.
Shares of Enliven Therapeutics (ELVN) are surging approximately +15% in premarket trading on March 25, 2026, driven by renewed investor enthusiasm around the company's advancing clinical program for ELVN-001 in chronic myeloid leukemia (CML). The stock's prior closing price on March 24, 2026 was $31.15, placing the premarket indicated price near $35.82.
AVXL shares are down approximately 29% in premarket trading on Wednesday, March 25, 2026, falling to roughly $2.97 from the prior close of $4.19. The primary catalyst is Anavex's formal withdrawal of its marketing authorization application (MAA) for blarcamesine from the European Union, announced in the early hours of March 25, 2026.
Shares of GSAT are surging approximately +15% intraday on March 25, 2026, following a prior session close of $61.09. The primary catalyst is a fresh analyst note from Scotiabank highlighting Globalstar's direct-to-device satellite connectivity bypassing cellular towers — most notably in Mexico — reinforcing the company's next-generation infrastructure thesis.
Shares of ADMA are declining approximately 12% in Wednesday's session, extending a steep two-day selloff. The primary catalyst is a short-seller research report published by Culper Research on March 24, 2026, alleging that ADMA engaged in channel stuffing to artificially inflate revenue growth.
Honeywell International (HON) and TransDigm Group (TDG) are prominent players in the aerospace and industrials sector, benefiting from rising air travel demand, defense spending, and aftermarket services. This stock comparison evaluates their business models, recent performance, and market positioning to help traders and investors assess relative strengths in the current environment. With global aviation recovery and geopolitical tensions supporting sector tailwinds, professionals seeking exposure to aerospace growth versus diversified industrials stability will find these insights relevant for portfolio decisions and relative performance analysis.